This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter: revenue up 27% and profit after tax up 83% year on year
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 3.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue from operations rose 27% to Rs 82,624 lakh from Rs 65,279 lakh a year earlier, while profit after tax rose 83% to Rs 8,277 lakh from Rs 4,516 lakh. For the consolidated half year ended September 30, 2026, revenue was Rs 1,52,903 lakh and profit after tax was Rs 13,249 lakh. Auditors gave an unmodified opinion; previous-quarter figures were regrouped or rearranged.
Strong quarterly growth and an unmodified audit opinion may support positive investor sentiment, although no company guidance was provided.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹826.2 Cr | ₹652.8 Cr | +26.6% |
| Operating profit | ₹106.7 Cr | ₹60.32 Cr | +76.9% |
| Profit after tax | ₹82.77 Cr | ₹45.16 Cr | +83.3% |
| EBITDA margin | 16.4% | 12.9% | +3.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.